PT-141 (bremelanotide), the melanocortin pathway, and what Vyleesi was actually approved for

Key takeaways

• Bremelanotide (Vyleesi) was approved by the FDA on June 21, 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) .
• The labeled dose is 1.75 mg subcutaneously via single-use autoinjector, taken at least 45 minutes before anticipated sexual activity, no more than one dose in 24 hours, and not more than 8 doses per month .
• The pivotal RECONNECT program (two identically designed Phase 3 trials, Kingsberg 2019, Obstetrics and Gynecology) randomized 1,247 premenopausal women with HSDD over 24 weeks. The drug arm showed a statistically significant advantage on the co-primary endpoints of desire score and distress score, with modest absolute effect sizes .
• Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease. The label warns about transient blood pressure increases and focal hyperpigmentation, particularly with more frequent dosing or darker skin tones .
• PT-141 is a melanocortin receptor agonist (binding MC1R through MC5R, with primary central activity through MC4R). The label does not approve it for men, postmenopausal women, or sexual-performance use, and research-vial intranasal preparations sold to the community are not the approved drug .

What Vyleesi actually is

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist. It was developed by Palatin Technologies and approved as Vyleesi by the FDA on June 21, 2019, with original commercialization through AMAG Pharmaceuticals and later rights changes that left the prescribing information owned by Palatin and partners .

The approved indication is narrow. Per the current US label, Vyleesi is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder, characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance. It is not approved for men, not approved for postmenopausal women, and not approved as a treatment for sexual performance .

Mechanism: the melanocortin receptor family

Bremelanotide binds the melanocortin receptor family (MC1R through MC5R) as a non-selective agonist, with the central effect on sexual desire generally attributed to MC4R signaling in the hypothalamus. MC4R is the same receptor that the rare-disease drug setmelanotide (Imcivree) targets selectively in genetic obesity, and it is the receptor most strongly implicated in central control of appetite and sexual function .

Other melanocortin receptor activities account for the recognizable side-effect profile. MC1R activation on melanocytes contributes to the focal hyperpigmentation that the Vyleesi label discusses. Peripheral MC receptor effects contribute to the transient blood-pressure rise that is the basis of the cardiovascular warning, and central MC4R activity contributes to nausea, which is the most common adverse event in the trials.

RECONNECT: what the pivotal trials actually measured

The RECONNECT program (Kingsberg 2019, Obstetrics and Gynecology) consisted of two identically designed Phase 3 randomized, double-blind, placebo-controlled trials (Study 301 and Study 302) of bremelanotide 1.75 mg subcutaneous as needed versus placebo for 24 weeks, in premenopausal women with acquired, generalized HSDD. Combined enrollment was 1,247 women across the two studies. The co-primary endpoints were change from baseline in the Female Sexual Function Index desire-domain score and the Female Sexual Distress Scale Desire/Arousal/Orgasm distress item 13 score .

Both studies met the co-primary endpoints. The desire-score advantage of bremelanotide over placebo was statistically significant in each trial, and the distress-score reduction was likewise statistically significant. Absolute effect sizes were modest on continuous scales. Responder analyses, defined as a clinically meaningful within-patient change on the desire and distress endpoints, also favored bremelanotide. The label discusses these results without translating them into a marketing-style efficacy headline because the underlying scale changes are small in absolute terms .

The label also describes a long-term safety extension study and pooled adverse-event data across the pivotal program. The most common adverse reactions in the pooled data were nausea (about 40 percent), flushing, injection-site reactions, headache, and vomiting, with most events occurring within the first dose or first few doses and resolving without intervention .

Safety profile: blood pressure, pigmentation, and contraindications

Vyleesi labeling describes a transient increase in blood pressure that peaks within hours after each dose and resolves within about 12 hours. Mean increases reported in the trial program were on the order of about 6 mmHg systolic and 3 mmHg diastolic. Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease and is not recommended in patients at high risk for cardiovascular disease .

Focal hyperpigmentation is the second recognizable label item. The pivotal trials reported new or worsening hyperpigmentation, particularly on the face, gums, and breasts, in roughly 1 percent of patients receiving bremelanotide, with higher prevalence in those who received more than 8 doses per month and in patients with darker baseline skin tone. The pigmentation may not be fully reversible after discontinuation in all cases .

• Do not use in patients with uncontrolled hypertension or known cardiovascular disease.
• Do not exceed one dose in 24 hours or 8 doses per month.
• Discontinue if HSDD symptoms do not improve after 8 weeks of treatment.
• Counsel on the possibility of focal hyperpigmentation, especially in darker skin tones and with more frequent dosing.
• Nausea is most frequent after the first dose and typically resolves; severe nausea warrants discontinuation.

Off-label, research-vial, and intranasal claims

Community discussion of PT-141 frequently treats the molecule as a general-purpose sexual-performance enhancer for men, for older women, and for partners using research-vial intranasal preparations sold by online suppliers. None of these uses corresponds to the FDA-approved indication. The pivotal Phase 3 program enrolled premenopausal women with a specific diagnostic profile, used a specific subcutaneous autoinjector at a specific dose, and read out endpoints related to desire and distress, not erection or orgasm .

Earlier-stage clinical work on intranasal bremelanotide in men with erectile dysfunction reported pharmacodynamic effects on erection, but that program did not advance to an approved label, partly because of the blood-pressure profile. The decision to bring forward the female-HSDD indication at the 1.75 mg subcutaneous autoinjector dose was a deliberate development choice; it is not a sign that the intranasal route is interchangeable with the approved one .

Research-vial bremelanotide sold as a lyophilized powder online is not the FDA-approved product. The identity, purity, sterility, and dose accuracy of those preparations cannot be assumed from the Vyleesi trial program. The FDA's posture on peptide bulk substances and on compounded preparations is unchanged by the Vyleesi approval; the trial drug and the autoinjector are the only basis for the label claims .

What the data does and does not say

• Yes: an FDA-approved subcutaneous melanocortin receptor agonist exists for premenopausal women with acquired, generalized HSDD.
• Yes: the pivotal Phase 3 program met its co-primary endpoints with modest absolute effect sizes on desire and distress scales.
• Yes: the label includes a transient blood-pressure warning, a contraindication in uncontrolled hypertension, and a focal-hyperpigmentation warning.
• No: there is no approved bremelanotide indication for men, for postmenopausal women, for general libido enhancement, or for sexual-performance use.
• No: research-vial intranasal PT-141 is not the trial drug. The trial data does not transfer route-by-route to a route the program did not test.

For research and educational purposes only. Not medical advice. The decision to use Vyleesi or any sexual-health therapy should involve a qualified clinician who can review individual cardiovascular risk, blood pressure history, current medications, and the specifics of the HSDD diagnostic profile.

Editorial summary

PT-141 became Vyleesi by passing a focused Phase 3 program in a narrow indication. The mechanism is melanocortin receptor agonism, with the central sexual-desire effect attributed to MC4R. The approved dose is 1.75 mg subcutaneously as needed in premenopausal women with acquired, generalized HSDD, with a transient blood-pressure rise and focal hyperpigmentation as the recognizable label items. Everything outside that indication, including male use, postmenopausal use, intranasal research-vial use, and routine sexual-performance use, sits outside the trial data the FDA used to grant the approval.

Related tools

• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
• BAC water calculator - Solve BAC water volume for a target concentration.
• Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
• Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.